Inactive Instrument

News Algeta ASA Xetra

Stocks

GJ9

NO0010239437

Biotechnology & Medical Research

End-of-day quote Xetra
- ^EUR	-

14-05-06	Actavis : Factbox - M&A frenzy transforming global pharma	RE
14-05-06	Actavis : M&A frenzy in healthcare sector	RE

All News

Mentions Relevance

14-03-23	Algeta ASA : UK cost agency says 'no' to Bayer prostate cancer drug Xofigo	RE
14-02-24	Algeta ASA : Bayer clinches $2.9 billion deal for Norway's Algeta	RE
13-11-18	Algeta ASA : Algeta to host Capital Markets Days	PU
13-11-08	Algeta ASA : Algeta's Financial Calendar 2014	PU
13-11-08	Algeta ASA : CORRECTION: Algeta ASA : Algeta Results for the Third Quarter 2013	PU
13-11-05	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
13-10-28	Algeta ASA : Algeta Schedules Third Quarter 2013 Results Presentation, Webcast and Conference Call	PU
13-09-12	Algeta ASA : New data and analyses from the phase III ALSYMPCA trial of radium Ra 223 dichloride to be presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013	PU
13-08-28	Algeta ASA : Algeta results for the First Half and Second Quarter 2013	PU
13-08-19	Algeta ASA : Algeta schedules first half and second quarter 2013 results presentation, webcast and conference call	PU
13-08-19	Algeta ASA : Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer	PU
13-08-12	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
13-06-20	Algeta ASA : Algeta celebrates the official opening of its commercial production facility for Xofigo® (radium Ra 223 dichloride) at the Institute for Energy Technology (IFE) in Norway	PU
13-06-11	Algeta ASA : Algeta to evaluate novel Targeted Thorium Conjugate (TTC) based on Avipep's Avibody platform	PU
13-05-30	Algeta ASA : Algeta announces first sale of Xofigo® (radium Ra 223 dichloride) in the United States	PU
13-05-16	Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at ASCO	PU
13-05-15	Algeta ASA : Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA	PU
13-05-15	Algeta ASA : Algeta results for the first quarter 2013	PU
13-05-14	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
13-05-07	Algeta ASA : Algeta schedules first quarter 2013 results presentation, webcast and conference call	PU
13-05-02	Algeta ASA : Algeta exercises option and signs exclusive license agreement with Lumiphore, Inc. for novel technology for development of Targeted Thorium Conjugates (TTCs)	PU
13-04-17	Algeta ASA : Algeta to Participate in Upcoming Investor Conference	PU
13-03-20	Algeta ASA : Algeta - Notice of Annual General Meeting 2013	PU
13-02-20	Algeta ASA : Algeta to Participate in Upcoming Investor Conferences	PU
13-01-28	Algeta ASA : Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody	PU